Keyphrases
Adverse Cardiac Events
8%
All-cause Mortality
6%
Cardiac Magnetic Resonance
12%
Cardioprotection
5%
Cardiovascular Mortality
16%
Clinical Outcomes
14%
Confidence Interval
13%
Coronary Artery Disease
14%
Culprit Lesion
6%
Deferred Stenting
5%
Denmark
6%
Final Infarct Size
15%
Fractional Flow Reserve
11%
Glucocorticoid Therapy
14%
Hazard Ratio
9%
Infarct Size
21%
Ischemic Preconditioning
14%
LDL Cholesterol
5%
Left Ventricular Function
14%
Long-term Mortality
6%
Meta-analysis
14%
Methylprednisolone
9%
New-onset Atrial Fibrillation
14%
Optimal Medical Therapy
14%
Oral Anticoagulants
14%
Patients with Coronary Artery Disease
5%
Percutaneous Coronary Intervention
32%
Percutaneous Coronary Revascularization
8%
Placebo
13%
Prehospital Setting
10%
Primary Percutaneous Coronary Intervention
46%
Prognostic Implications
14%
Prognostic Outcome
14%
Pulse Dose
17%
Randomized Clinical Trial
14%
Randomized Controlled Trial
17%
Recurrent Myocardial Infarction
7%
Remnant Cholesterol
14%
Residual Stenosis
5%
Revascularization
5%
Right Coronary Artery
6%
Right Ventricular Myocardial Infarction
14%
ST-elevation Myocardial Infarction (STEMI)
100%
Stable Flow
5%
Stenosis
5%
Systematic Meta-analysis
14%
Target Vessel Revascularization
5%
Thrombectomy
14%
Medicine and Dentistry
Antithrombotic
14%
Cardiovascular Mortality
14%
Combination Therapy
14%
Coronary Artery Disease
14%
Fractional Flow Reserve
11%
Hazard Ratio
6%
Heart Muscle Revascularization
8%
Infarction
14%
Ischemic Postconditioning
14%
Major Adverse Cardiac Event
8%
Meta-Analysis
14%
Myocardial Infarction
19%
New-Onset Atrial Fibrillation
14%
Percutaneous Coronary Intervention
23%
Primary Percutaneous Coronary Intervention
29%
Revascularization
8%
Right Ventricle
6%
ST Segment Elevation Myocardial Infarction
50%
Stenting
14%
Systematic Review
14%
Thrombectomy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Alginic Acid
6%
All Cause Mortality
12%
Anticoagulant Agent
14%
Brain Ischemia
6%
Cardiovascular Mortality
14%
Glucocorticoid
28%
Heart Failure
5%
Heart Infarction
18%
Infarction
32%
Inflammation
5%
Low Density Lipoprotein Cholesterol
14%
Methylprednisolone
8%
New-Onset Atrial Fibrillation
14%
Placebo
13%
Randomized Clinical Trial
14%
Randomized Controlled Trial
14%
ST Segment Elevation Myocardial Infarction
79%
